Navigation Links
CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Date:8/20/2008

VIENNA, Va., Aug. 20 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) reports financial results for the three and nine months ending June 30, 2008.

The Company's loss from operations for the quarter ended June 30, 2008 was $2,176,679 versus a loss of $3,776,263 during the same quarter in 2007. The Company's loss from operations for the nine months ended June 30, 2008 was $7,129,215 versus a loss of $7,368,779 during the same nine months in 2007.

The net loss per common share for the quarter ended June 30, 2008 was $0.02 versus a net loss per common share of $0.05 during the same quarter in 2007. The Company's net loss per common share for the nine months ended June 30, 2008 was $0.06 versus a net loss per common share of $0.10 during the same nine month period in 2007.

During the three month period ended June 30, 2008, research and development charges were $975,183 compared to $632,868 during the same period in 2007. During the nine month period ended June 30, 2008, research and development expenses were $3,041,212 compared to $1,817,891 during the same period in 2007.

During the three month period ended June 30, 2008, general and administrative expenses were $1,177,288 compared to $3,104,755 during the same period in 2007. During the nine month period ended June 30, 2008, general and administrative expenses were $3,931,857 compared to $5,473,605 during the same period in 2007.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "We are moving forward just as we had planned. The greatest part of the expenditures are focused on completing the manufacturing facility and starting the Phase III study of our Multikine cancer drug. Some additional funds were spent on our new and very promising Rheu
'/>"/>

SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI to Present at the Noble Financial Conference
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Calif. , April 23, 2015  Cryoport, ... advanced cryogenic logistics solutions for the life sciences ... established its cryogenic logistics solutions within the animal ... with Yancey Farms to support the shipment of ... German Sport horse Stallions. Animal ...
(Date:4/23/2015)... Glemser Technologies is ... Enterprise Content Division (ECD) Certified Solution Partner to ... for Life Sciences Solution Suite . The accreditation ... to provide life sciences companies of all sizes ... EMC Documentum Solution Suite offers four modules: Quality ...
(Date:4/23/2015)... April 23, 2015  Propanc Health Group Corporation ... focuses on the development of cancer treatments for ... lead product includes PRP, a patented formulation consisting ... as well as the enzyme amylase designed to ... a combination of anti-cancer agents working in combination ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... 4, 2013 /Press Release/ Toxic waste sites with ... of "healthy years of life lost" in individuals living near ... a study by a Mount Sinai researcher published online today ... Kevin Chatham-Stephens, MD, Pediatric Environmental Health Fellow at the Icahn ...
... ON New research indicates that Mexican-Americans born in the ... significantly more likely than Mexican-American immigrants to report that ... physical activities such as walking, climbing stairs, reaching, lifting, ... in this week,s International Journal of Environmental Research ...
... 2, 2013 CDX Diagnostics, Inc ("CDX") and Shared ... patent infringement action against Histologics, LLC, Poplar HealthCare, PLLC ... Avero Diagnostics (collectively, "Defendants") in the United States District ... York . According to court documents, CDX and ...
Cached Biology News:Toxic waste sites cause healthy years of life lost 2Older US-born Mexican-Americans more physically limited than Mexican-American immigrants: Study 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Biology Products: